Last reviewed · How we verify
Chemotherapy (Gemcitabine + Carboplatin or Eribulin) (chemotherapy-gemcitabine-carboplatin-or-eribulin)
Chemotherapy (Gemcitabine + Carboplatin or Eribulin) (generic name: chemotherapy-gemcitabine-carboplatin-or-eribulin) is a drug developed by Pfizer Inc.. It is currently in Phase 1 development.
Gemcitabine and carboplatin disrupt DNA synthesis and repair, while eribulin inhibits microtubule dynamics, leading to cell death in rapidly dividing cancer cells.
Gemcitabine + Carboplatin or Eribulin is a cytotoxic chemotherapy regimen developed and used by Pfizer for treatment of solid tumors, particularly metastatic and triple-negative breast cancer, urothelial carcinoma, and other advanced malignancies. The combination works through dual mechanisms: gemcitabine (a nucleoside analog) inhibits ribonucleotide reductase and incorporates into DNA to disrupt replication, while carboplatin (a platinum alkylating agent) or eribulin (a microtubule destabilizer) provides complementary cytotoxic activity. Currently in Phase 1 development within Pfizer's pipeline, the regimen is being evaluated in multiple Phase 2 and Phase 3 trials across breast cancer subtypes and urothelial carcinoma, including the SAFIR02_Breast trial (N=1,460) and ROSETTA Breast-01 (N=558). Clinical differentiation centers on genomic-guided patient selection and combination with targeted agents (e.g., ipatasertib, inetetamab, pumitamig) to enhance efficacy in molecularly defined populations. The commercial significance is substantial given the large patient populations in metastatic breast cancer and bladder cancer; gemcitabine and carboplatin are established standard-of-care agents with multi-billion-dollar annual utilization globally. Pipeline expansion includes biomarker-driven trials and combination strategies with immunotherapy and targeted kinase inhibitors.
At a glance
| Generic name | chemotherapy-gemcitabine-carboplatin-or-eribulin |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Mechanism of action
Gemcitabine and carboplatin work by interfering with DNA replication and repair processes, which are crucial for cell division. Eribulin, on the other hand, blocks the formation of microtubules, essential structures for cell division, thereby preventing cancer cells from multiplying.
Approved indications
Common side effects
- Anemia
- Fatigue
- Generalized muscle weakness
- Infections and infestations - Other, Bacteremia
- Neutrophil count decreased
- Platelet count decreased
- White blood cell decreased
- Febrile Neutropenia
- Dysgeusia
- Gastrointestinal disorders - Other, Hernia
- Hyponatremia
- Thromboembolic event
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotherapy (Gemcitabine + Carboplatin or Eribulin) CI brief — competitive landscape report
- Chemotherapy (Gemcitabine + Carboplatin or Eribulin) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI